Navigation Links
EndoSphere Inc. Announces Pivotal Financing Led by Broadline Capital
Date:6/1/2011

COLUMBUS, Ohio, June 1, 2011 /PRNewswire/ -- EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of a highly oversubscribed Series A Preferred Financing round led by Broadline Capital, a global private equity investment firm.  EndoSphere Inc., which holds 23 U.S. and international issued and pending patents, will use the funding to expand its intellectual property assets and to complete additional clinical product testing.

"EndoSphere is extremely fortunate to align itself with Broadline Capital, which offers a rare blend of global financial expertise and pragmatic operating experience," said James McKinley, EndoSphere CEO.

Broadline Capital was formed in 2005 by Christopher Thorne, an early pioneer in China's private equity industry and former management consultant at McKinsey & Company.  Thorne previously founded and developed a software technology company that created efficiency gains for manufacturers, distributors and retailers in the trillion-dollar food and beverage, consumer packaged goods and retail supply chains.  The resulting company sold to institutional investors at a nine-figure enterprise valuation in 2007.

"An investment in EndoSphere presented us with a unique opportunity to invest in, and support, an exciting portfolio of intellectual property assets and a highly experienced management team," said Thorne. "EndoSphere's technology brings an innovative approach to treating obesity, which has become one of the largest health problems worldwide."

The company is planning a multi-center clinical trial while continuing its research and development of innovative and profitable applications.  

"With the support of this financing, EndoSphere is poised to fulfill the potential of the technology and the expectations of the investors," commented McKinley.

Broadline Capital's co-investing partners in EndoSphere's Series A Preferred Financing include investment firm Glengary LLC, Physician Investment Group LLC, and several of the nation's largest angel investment funds including Ohio TechAngel Funds II and III, North Coast Angel Fund II, and QCA First Fund III.

About EndoSphere Inc.

EndoSphere Inc. is a medical technology company that develops and commercializes devices including the SatiSphere™ duodenal insert, which treats one of the most critical healthcare issues in the world today: obesity and its co-morbidities. EndoSphere is a Delaware corporation founded in 2006 in Redwood City, California and is now headquartered in Columbus, Ohio.

About Broadline Capital

Broadline Capital is a global private equity investment firm with offices in the U.S. and China.  The firm was founded in 2005 by Christopher Thorne to provide capital, expertise and management support to promising companies within highly charged markets. Leading some of the most creative deals in its market categories, Broadline Capital received the private equity industry's "Deal of the Year" award in Asia, named by Private Equity International for a 2007 China investment.  For more information about Broadline Capital, please visit www.BroadlineCapital.com.

Contact:
Bryan Kozlowski, Financial Controller
EndoSphere Inc.
Phone: 614.245.0338


'/>"/>
SOURCE EndoSphere Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. ... board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... Yorba Linda, Ca (PRWEB) , ... April 28, ... ... entities with cardiac or hERG liability could substantially improve drug safety and minimize ... will be provided for validating ion channel inhibition using cell lines and for ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
Breaking Medicine News(10 mins):